ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2019 American Transplant Congress

    Evaluation of Infection and Renal Transplant Outcomes in the Hmong Population

    M. Jorgenson1, J. Descourouez1, D. Yang2, G. Leverson2, J. Smith2, R. Redfield2

    1UW Health, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    *Purpose: Literature suggests the Hmong people to be at higher risk for infection, particularly fungal. The risk of infection after transplant in the Hmong population…
  • 2019 American Transplant Congress

    The Effects of Chronic Kidney Disease on Antiviral T Cell Response

    R. L. Crepeau1, H. Li2, L. P. Daley-Bauer3, M. L. Ford1, P. D. Winterberg2

    1Emory Transplant Center, Atlanta, GA, 2Pediatrics, Emory University School of Medicine, Atlanta, GA, 3Microbiology & Immunology, Emory University School of Medicine, Atlanta, GA

    *Purpose: Accumulation of memory T cells bearing markers of sustained antigen stimulation have been described in patients with chronic kidney disease (CKD). Cytomegalovirus (CMV) establishes…
  • 2019 American Transplant Congress

    Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 10 Years Follow-Up

    Y. Watarai1, S. Narumi1, T. Tomosugi1, K. Futamura2, M. Okada1, M. Tsujita2, T. Hiramitsu1, T. Kobayashi3, N. Goto2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 2Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3Kidney Transplantation, Aichi Medical University, Nagoya, Japan

    *Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…
  • 2019 American Transplant Congress

    Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation

    A. Asberg, G. B. Kro, A. V. Reisæter, A. Hartmann, K. Midtvedt

    Oslo University Hospital - Rikshospitalet, Oslo, Norway

    *Purpose: Cytomegalovirus (CMV) naïve kidney transplant recipients (R-) transplanted with an organ from a CMV positive donor (D+) are at high risk for CMV disease.…
  • 2019 American Transplant Congress

    The Effect Of Tacrolimus Trough Variability On Kidney Transplant Outcomes

    S. Heeney1, K. R. Szempruch1, R. Lee1, A. Mintz2, P. Serrano1, R. Detwiler1, C. Doligalski1

    1University of North Carolina Medical Center, Chapel Hill, NC, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC

    *Purpose: High variability in tacrolimus as assessed by tacrolimus coefficient of variability (TCV) in trough levels of kidney transplant recipients (KTRs) has been associated with…
  • 2019 American Transplant Congress

    Risk of Opportunistic Infection in Kidney Transplant Recipients with Cytomegalovirus Infection and Associated Outcomes

    M. Jorgenson1, J. Descourouez1, B. Cardinale2, B. Lyu3, B. Astor3, N. Garg3, C. Saddler3, J. Smith3, D. Mandelbrot3

    1UW Health, Madison, WI, 2University of Wisconsin-Madison School of Pharmacy, Madison, WI, 3University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI

    *Purpose: Cytomegalovirus (CMV) infection in kidney transplant recipients has been anecdotally observed with concomitant or subsequent opportunistic infections (OI), but this association has yet to…
  • 2019 American Transplant Congress

    Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection

    O. Beaird1, M. Carlson1, P. Gaynor1, D. Nanayakkara1, B. Abdalla2, S. Bunnapradist2, J. Schaenman1

    1Department of Internal Medicine - Division Infectious Diseases, UCLA, Los Angeles, CA, 2Department of Internal Medicine - Division Nephrology, UCLA, Los Angeles, CA

    *Purpose: To describe our clinical experience using a CMV Specific Cell Mediated Immunity (CMI) assay in solid organ transplant (SOT) recipients with late-onset CMV, defined…
  • 2019 American Transplant Congress

    Incidence of Viral Infections in Kidney Transplant Recipients with Alemtuzumab or Rabbit Antithymocyte Globulin Induction

    A. Brueckner1, C. Truong1, E. Yanqui1, R. Baliga2, L. Bowman1

    1Tampa General Hospital, Tampa, FL, 2Florida Kidney Physicians, Tampa, FL

    *Purpose: Monoclonal antibody therapy causes profound and sustained lymphocyte depletion thus increasing the risk of viral infections. While studies exist evaluating the outcomes of alemtuzumab…
  • 2019 American Transplant Congress

    CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes

    G. Karadkhele, W. Zhang, C. P. Larsen

    Emory University, Atlanta, GA

    *Purpose: Intensification of immunosuppression using T cell depleting induction has reduced rates of acute cellular rejection after kidney transplantation. Belatacept, a first in class T…
  • 2019 American Transplant Congress

    Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients

    A. L. Bixby, L. Fitzgerald, L. Cotiguala, J. M. Park, D. Kaul, C. Sonnenday, S. Tischer

    Michigan Medicine, Ann Arbor, MI

    *Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences